ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Position Lowered by GSA Capital Partners LLP

GSA Capital Partners LLP decreased its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 75.5% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 35,313 shares of the biotechnology company’s stock after selling 109,045 shares during the period. GSA Capital Partners LLP’s holdings in ADMA Biologics were worth $706,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quest Partners LLC purchased a new position in ADMA Biologics during the second quarter valued at approximately $29,000. Hollencrest Capital Management purchased a new stake in ADMA Biologics in the 3rd quarter worth approximately $30,000. EntryPoint Capital LLC acquired a new stake in shares of ADMA Biologics during the 1st quarter valued at $31,000. CWM LLC grew its holdings in shares of ADMA Biologics by 114.2% during the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after acquiring an additional 4,367 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new position in shares of ADMA Biologics in the second quarter worth $93,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Trading Down 5.7 %

Shares of NASDAQ:ADMA opened at $19.04 on Monday. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $4.50 billion, a PE ratio of 68.00 and a beta of 0.64. ADMA Biologics, Inc. has a 1 year low of $3.60 and a 1 year high of $23.64. The firm has a fifty day moving average price of $18.54 and a 200 day moving average price of $14.40.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same quarter in the previous year, the firm earned $0.01 earnings per share. Analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on ADMA shares. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a research report on Friday, September 20th. HC Wainwright lifted their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th. Finally, Raymond James boosted their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th.

Insider Buying and Selling

In related news, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now owns 2,059,726 shares in the company, valued at $36,436,552.94. This trade represents a 10.31 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now directly owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This represents a 5.52 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is currently owned by insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.